Search

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Accuracy of the ChemoFx Chemoresponse Assay in Patients With Recurrent Ovarian, Peritoneal, or Fallo
Adjuvant Intraperitoneal Carboplatin With Paclitaxel in Treating Patients Who Had Initial Debulking
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recur
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage
Carboplatin Plus Docetaxel, Paclitaxel and Bevacizumab in Treating Patients With Stage III or Stage
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian E
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Level
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritonea
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persis
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage I
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Periton
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surger

Comprehensive Cancer Control Plan

The Cherokee Nation Comprehensive Cancer Control (CNCCC) Project assists in the development of networks and collaboration that produce an infrastructure for a comprehensive approach to cancer within the Cherokee Nation. Since 2003, coalition members and partners have come together to discuss the burden of cancer in Cherokee Nation. Coalition members and partners include local, regional, state and national representatives committed to identifying areas of cancer concern, planning interventions, prioritizing greatest areas of identified need, and then implementing identified strategies and/or providing needed resources. This is the second edition of the Cherokee Nation Comprehensive Cancer Control Plan and will serve, like the first, as an information resource for health care professionals and community members, as well as a tool for the Cherokee Nation Comprehensive Cancer Control Coalition and its respective entities. The coalition is committed to the process of enhancing infrastructure for comprehensive cancer control in the Cherokee Nation with the ultimate goal of reducing morbidity and mortality among the Cherokee community.